Cannabis Market in Israel

Israel has been a global pioneer in cannabis research, with its scientific contributions dating back to the 1960s when Professor Raphael Mechoulam at the Hebrew University of Jerusalem first isolated and synthesized THC and later discovered the endocannabinoid system. This research legacy has given Israel a unique position in the global cannabis industry, with the country hosting more cannabis-related clinical trials per capita than any other nation. The Israeli government's supportive stance toward cannabis research has attracted companies and researchers from around the world.

Israel's medical cannabis program was established in 2007 and has grown to serve over 100,000 patients. The Israel Medical Cannabis Agency (IMCA) oversees the program, which allows patients with qualifying conditions to receive cannabis prescriptions. The market has evolved from a small, closely regulated program to a more accessible system, with reforms in 2019 expanding the number of licensed producers and pharmacies authorized to dispense cannabis. Patients can access flower, oils, capsules, and other products through licensed pharmacies.

The Israeli cannabis industry has developed a strong focus on technology, genetics, and pharmaceutical-grade products. Companies like IM Cannabis Corp, Tikun Olam, Bazelet, and numerous startups operate across the value chain from cultivation to technology platforms. Israeli cannabis technology companies have developed innovations in areas including automated cultivation systems, precision dosing, novel delivery mechanisms, and data analytics platforms. The country's startup ecosystem and venture capital infrastructure support cannabis innovation in ways that few other markets can match.

Export legalization in 2020 opened a significant growth vector for Israeli cannabis companies, allowing them to sell medical cannabis to international markets. This was a long-anticipated development that could leverage Israel's cultivation expertise and quality reputation. However, the implementation has been gradual, with regulatory processes and international market access requiring time to develop. Israel's proximity to European markets and its pharmaceutical industry credibility make it a natural supplier for the growing European medical cannabis market, particularly in Germany and the UK.